Lupin receives USFDA's approval for Fosaprepitant for injection

06 Sep 2019 Evaluate

Lupin has received approval for its Fosaprepitant for Injection, 150 mg Single-Dose Vial, from the United States Food and Drug Administration (USFDA). Lupin's Fosaprepitant for Injection,  is the generic version of Emend for Injection, 150 mg Single-Dose Vial, of Merck Sharp & Dohme Corp. (Merck)

It is indicated for adults in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemot herapy (MEC).

Fosaprepitant for Injection, 150 mg Single-Dose Vial, had annual sales of approximately USD 285 million in the US (IQVIA MAT June 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2118.35 -32.70 (-1.52%)
01-Feb-2026 13:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1617.20
Dr. Reddys Lab 1222.60
Cipla 1313.60
Zydus Lifesciences 885.50
Lupin 2118.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×